Medidata Delivers a Decade of AI Leadership to 500+ Clinical Studies and Growing

Core Insights - Medidata is enhancing clinical trial success through AI technologies, benefiting over 500 clinical studies in the last decade, with more than 120 AI-supported studies initiated in 2025 [1][3] Group 1: AI Advancements - Medidata has introduced significant enhancements to its platform, including Medidata AI Study Build, which accelerates study builds by utilizing study protocols and generative AI, leading to faster time-to-market for sponsors [2][6] - The company is expanding its core AI orchestrator, Dot, which connects domain-specific AI Companions across the platform, providing clear visibility and accelerating the use of AI in clinical trials [5][6] Group 2: Industry Impact - Medidata's AI is transforming clinical trials by leveraging a large clinical data set from over 38,000 trials, focusing on clinically-fluent, regulatory-grade AI to drive results throughout the trial lifecycle [3][6] - The life sciences industry is increasingly adopting embedded, enterprise AI solutions, with Medidata's AI Study Build poised to revolutionize complex database build processes and enhance market access [6] Group 3: Company Overview - Medidata has been a leader in clinical trial solutions for 25 years, supporting over 37,000 trials and 11 million patients, with more than 1 million registered users across approximately 2,300 customers [7] - The company is recognized for its technological innovation and has been acknowledged as a Leader by Everest Group and IDC [7]